

January 23, 2020



Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer

LYON, France--(BUSINESS WIRE)-- [POXEL SA](#) (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO). Dr. Moller will be responsible for leading scientific-related activities to support the advancement of the Company, including scientific innovation and scientific communications at Poxel. Dr. Moller is an industry leader in the discovery and development of new therapeutic agents, particularly in diabetes and metabolic disorders. He will be based in Boston, further expanding Poxel's presence in the U.S.

Dr. Moller will join the executive management team and work closely with the R&D team in France, including Sébastien Bolze, PharmD, PhD, who has been appointed to the newly created position of Chief Operating Officer, Executive Vice President, Non-Clinical & Manufacturing Operations. In this new role, Dr. Bolze will oversee and coordinate R&D operations.

"With an unmatched depth of expertise in metabolic disease research and drug development, David is a valuable addition to Poxel's senior management team. This is a critical and exciting time for the Company as we support our partners Sumitomo Dainippon Pharma with product registration for Imeglimin in Japan, and Metavant, a subsidiary of Roivant Sciences, with their preparation for a Phase 3 program for Imeglimin in the U.S. and Europe, while advancing our two NASH programs, PXL770 and PXL065, through key clinical studies," commented Thomas Kuhn, CEO of Poxel. "David is a highly respected medical expert and scientific leader and we look forward to his contributions as Poxel continues to establish itself at the forefront of innovation in treating metabolic diseases."

"I am thrilled to join Poxel at this stage of the Company's evolution. With the successful completion of the Phase 3 program for Imeglimin in Japan, Poxel has achieved a significant milestone for this innovative product candidate; this is a major achievement, especially in a large indication like type 2 diabetes," said Dr. Moller, CSO of Poxel. "I am excited to join the Company to support the next phase of pipeline development, build momentum in the two NASH clinical programs and apply my experience to complement the Poxel team in expanding its early stage drug development efforts."

Dr. Moller brings over 20 years of experience leading R&D efforts at Eli Lilly and Company and Merck, where he focused on cardiometabolic drug discovery and development as well as other disease areas including endocrine and musculoskeletal disorders. He joins Poxel from Sigilon Therapeutics, where as CSO he led the company's rare disease and type 1 diabetes

efforts. Prior to that, Dr. Moller served in senior roles at Eli Lilly over a twelve-year period, including Vice President (VP) of Endocrine and Cardiovascular Research and Clinical Investigation and VP of Business Development – Emerging Technology and Innovation. Importantly, his team was responsible for the development of Trulicity[®] (dulaglutide) and other key product candidates. Prior to Eli Lilly, Dr. Moller served in senior roles over a ten-year period at Merck. As VP of Metabolic Disorders, he led the global diabetes and obesity discovery area, which included oversight of the team that discovered Januvia[®] (sitagliptin).

Dr. Moller obtained a BS from Brown University and a Doctor of Medicine degree from the University of Cincinnati. He began his career as Assistant Professor at Harvard Medical School focused on elucidating the pathophysiology of type 2 diabetes, where he had also completed a research and clinical postdoctoral fellowship in Endocrinology. He has published more than 130 peer-reviewed papers. His honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an Adjunct Professor at the Karolinska Institute.

About Poxel SA

Poxel is a **dynamic biopharmaceutical company** that uses its extensive expertise in developing **innovative drugs for metabolic diseases**, with a focus on **type 2 diabetes** and **non-alcoholic steatohepatitis (NASH)**. In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. **Imeglimin**, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel successfully completed the Phase 3 Trials of **IMeglimin** for **Efficacy and Safety (TIMES)** program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. **PXL065** (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

*Trulicity[®] is a registered trademark of Eli Lilly and Company and Januvia[®] is a registered trademark of Merck and Co.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200122005563/en/>

Poxel SA

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

+1 617 818 2985

Aurélie Bozza

Investor Relations and Communication Director

aurelie.bozza@poxelpharma.com

+33 6 99 81 08 36

Investor relations / Media - EU/US

Trophic Communications

Stephanie May or Valeria Fisher

may@trophic.eu or fisher@trophic.eu

+49 89 238 877 34 or +49 89 909 338 02

Investor relations / Media - France

NewCap

Alexia Faure or Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

Source: Poxel SA